Get the Stockscreener App
19.61
0.36%
0.07
After Hours:
19.61
Apellis Pharmaceuticals Inc stock is traded at $19.61, with a volume of 1.45M.
It is up +0.36% in the last 24 hours and down -30.73% over the past month.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
See More
Previous Close:
$19.54
Open:
$19.45
24h Volume:
1.45M
Relative Volume:
0.58
Market Cap:
$2.48B
Revenue:
$715.22M
Net Income/Loss:
$-250.10M
P/E Ratio:
-9.6601
EPS:
-2.03
Net Cash Flow:
$-205.58M
1W Performance:
-3.54%
1M Performance:
-30.73%
6M Performance:
+12.57%
1Y Performance:
-29.33%
1-Day Range:
$19.40
$19.95
1-Week Range:
$19.31
$20.57
52-Week Range:
$16.10
$35.72
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Name
Apellis Pharmaceuticals Inc
Sector
Industry
Phone
617-977-5700
Address
100 FIFTH AVENUE, WALTHAM, KY
Compare APLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
19.61 | 2.47B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-25 | Initiated | Wolfe Research | Peer Perform |
| Oct-15-25 | Initiated | Wells Fargo | Overweight |
| Sep-26-25 | Downgrade | Goldman | Neutral → Sell |
| May-09-25 | Downgrade | BofA Securities | Buy → Neutral |
| May-09-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-17-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-21-24 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-25-24 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-16-24 | Initiated | William Blair | Outperform |
| May-31-24 | Initiated | Piper Sandler | Neutral |
| Feb-05-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-02-23 | Initiated | Mizuho | Neutral |
| Oct-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-29-23 | Reiterated | Citigroup | Buy |
| Aug-03-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-01-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-10-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-19-22 | Initiated | H.C. Wainwright | Buy |
| Jun-17-22 | Resumed | Stifel | Buy |
| Apr-14-22 | Downgrade | ROTH Capital | Neutral → Sell |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-29-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-10-21 | Reiterated | BMO Capital Markets | Outperform |
| Sep-10-21 | Reiterated | Credit Suisse | Neutral |
| Sep-10-21 | Reiterated | Needham | Buy |
| Sep-10-21 | Reiterated | Oppenheimer | Outperform |
| Sep-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Aug-19-21 | Initiated | Jefferies | Buy |
| Aug-19-21 | Upgrade | Wedbush | Neutral → Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Nov-19-20 | Initiated | Needham | Buy |
| Sep-01-20 | Initiated | Stifel | Buy |
| Jul-20-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| Apr-01-20 | Initiated | Raymond James | Strong Buy |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-11-20 | Upgrade | Wedbush | Underperform → Neutral |
| Jan-07-20 | Initiated | SVB Leerink | Mkt Perform |
| Dec-19-19 | Initiated | BofA/Merrill | Buy |
| Nov-22-19 | Initiated | Wedbush | Underperform |
| Nov-05-19 | Initiated | Credit Suisse | Neutral |
| Aug-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-30-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| May-24-18 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Apellis Pharmaceuticals Inc Stock (APLS) Latest News
Can Apellis Pharmaceuticals Inc. stock beat analyst upgradesShare Buyback & AI Powered Market Entry Ideas - newser.com
Will Apellis Pharmaceuticals Inc. stock deliver better than expected guidanceQuarterly Growth Report & Daily Oversold Stock Bounce Ideas - newser.com
Does Apellis Pharmaceuticals Inc. (1JK) stock trade below intrinsic valueQuarterly Investment Review & Safe Entry Momentum Tips - newser.com
Apellis Pharmaceuticals Faces Weak Start with 17.3% Gap Down Amid Market Concerns - Markets Mojo
Why Apellis Pharmaceuticals Inc. (1JK) stock stays on buy listsShare Buyback & Safe Swing Trade Setups - newser.com
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough - 富途牛牛
Using AI based signals to follow Apellis Pharmaceuticals Inc.Gold Moves & Free Safe Entry Trade Signal Reports - newser.com
Apellis Pharmaceuticals Inc. stock prediction for this weekPortfolio Value Report & Stepwise Trade Execution Plans - newser.com
Risk vs reward if holding onto Apellis Pharmaceuticals Inc.2025 Price Action Summary & Real-Time Price Movement Reports - newser.com
Can Apellis Pharmaceuticals Inc. stock sustain market leadershipIndex Update & Weekly High Momentum Picks - newser.com
Can Apellis Pharmaceuticals Inc. stock resist sector downturnsTrade Exit Summary & Real-Time Buy Zone Alerts - newser.com
Will a bounce in Apellis Pharmaceuticals Inc. offer an exit2025 Bull vs Bear & Reliable Price Breakout Signals - newser.com
Why Apellis Pharmaceuticals Inc. stock is rated strong buyTrade Performance Summary & AI Powered Buy/Sell Recommendations - newser.com
Will Apellis Pharmaceuticals Inc. see short term momentum2025 Market Overview & AI Forecast for Swing Trade Picks - newser.com
Apellis Pharma general counsel Watson sells $100k in stock By Investing.com - Investing.com Canada
Apellis Pharma general counsel Watson sells $100k in stock - Investing.com
Apellis Pharmaceuticals General Counsel Sells 5,000 Shares - TradingView
[Form 4] Apellis Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Why Apellis Pharmaceuticals Inc. (1JK) stock could rally strongly2025 Bull vs Bear & Smart Money Movement Alerts - newser.com
Officer Watson Files To Sell 5,000 Of Apellis Pharmaceuticals Inc [APLS] - TradingView
Apellis Pharmaceuticals (BIT:1APLS) Price Target Decreased by 10.35% to 30.35 - Nasdaq
How Apellis Pharmaceuticals Inc. stock performs in weak economy2025 Growth vs Value & Fast Exit and Entry Strategy Plans - newser.com
What high frequency data says about Apellis Pharmaceuticals Inc.2025 Earnings Impact & Weekly High Momentum Picks - newser.com
Will breakout in Apellis Pharmaceuticals Inc. lead to full recovery2025 Short Interest & Real-Time Volume Triggers - newser.com
(APLS) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
How to build a dashboard for Apellis Pharmaceuticals Inc. stockVolume Spike & Free Daily Entry Point Trade Alerts - newser.com
Apellis Pharmaceuticals Inc Stock (APLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):